NCT02205333 - A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 13, 2014

Primary Completion Date

April 8, 2016

Study Completion Date

April 8, 2016

Conditions

Advanced Solid TumorsAggressive B-cell Lymphomas

Interventions

BIOLOGICAL

MEDI6469 Monotherapy

single intravenous (IV) administration of MEDI6469

BIOLOGICAL

MEDI6469 Plus Tremelimumab

MEDI6469 in combination with Tremelimumab

BIOLOGICAL

MEDI6469 Plus Durvalumab

MEDI6469 in combination with Durvalumab

BIOLOGICAL

MEDI6469 plus Rituximab

MEDI6469 in combination with Rituximab

Trial Locations (13)

7601

Research Site, Hackensack

20007

Research Site, Washington D.C.

28078

Research Site, Huntersville

33612

Research Site, Tampa

38120

Research Site, Memphis

48202

Research Site, Detroit

60611

Research Site, Chicago

77030

Research Site, Houston

85259

Research Site, Scottsdale

89169

Research Site, Las Vegas

90404

Research Site, Santa Monica

95817

Research Site, Sacramento

97213

Research Site, Portland